View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Aug. 31 (HealthDay News) -- Physicians' decisions to initiate growth hormone (GH) therapy in children with idiopathic short stature are mostly consistent with established guidelines, but their recommendations regarding GH continuation are more strongly influenced by contextual and attitudinal factors than by growth response to therapy, according to research published online Aug. 30 in Pediatrics.
J.B. Silvers, Ph.D., of Case Western Reserve University in Cleveland, and colleagues used a national census study of 727 pediatric endocrinologists to assess how physicians decide to initiate, intensify, or terminate GH treatment in patients with idiopathic short stature.
The investigators found that, in previously untreated children, recommendations to start GH treatment were in line with guidelines and affected by family preferences and physician attitudes. Among children treated with GH, the recommendation to continue GH treatment was dependent on growth response, but there were differences regarding course of action. In children with identical growth responses to GH treatment, independent, non-physiologic, and contextual factors drove physician decisions. The researchers determined that continuation decisions were influenced more by contextual and attitudinal factors than by growth response to therapy.
"With a potential market of 500,000 U.S. children and costs exceeding $10 billion per year, changes in GH use may depend on potentially modifiable physician attitudes and family preferences as much as physiologic evidence," the authors write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top